HATFIELD, England, January 23, 2015 /PRNewswire/ --
German Federal Joint Committee decision supports the needs of women with
advanced breast cancer in Germany
The German Federal Joint Committee (G-BA) today has confirmed that the largest defined patient group has "considerable" (beträchtlichen)[1] additional benefit of Halaven(R) (eribulin) versus certain comparator therapies as determined by the G-BA. Eribulin is approved for the treatment of women with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease.[1] Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting, unless patients were not suitable for these treatments.[2]
"The G-BA has made an encouraging decision potentially relevant for thousands of women in Germany with advanced breast cancer. Last year's indication extension for eribulin also means that women can have access to this important and effective treatment option earlier on. Eribulin remains the only single-agent chemotherapy proven to extend overall survival in metastatic breast cancer after anthracycline and taxane treatment, and this positive decision by the G-BA will be welcomed by physicians and patients across the country," said Dr Christian Jackisch Professor of Obstetrics and Gynaecology at the Breast Cancer Center Klinikum Offenbach, Germany.
The reassessment for eribulin is based on clinical evidence derived from two global Phase III trials; EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Treatment of Physician's Choice Versus E7389)[3] (Study 305) and Study 301.[4] These studies involved more than 1,800 women. In line with the G-BA requirements, additional pooled analyses of data were specifically performed for the benefit assessment procedure in Germany and reviewed by IQWiG.
Breast cancer is the most common form of cancer in women in Germany, and is associated with the highest number of deaths.[5] There were over 70,000 diagnosed cases of breast cancer in German women in 2012 with over 16,000 deaths resulting from the disease.[5]
"Eisai is delighted with the G-BA's decision, which clearly recognises the statistically significant and clinically relevant overall survival benefit of eribulin in women with metastatic breast cancer. Eribulin has already benefited more than 11,000 women in Germany over the past three years," commented Gary Hendler, President & CEO, Eisai EMEA and President, Eisai Oncology Global Business Unit.
First approved in 2011, eribulin received Marketing Authorisation Approval (MAA) for earlier use in advanced or metastatic breast cancer from the European Commission on 3 July 2014.
Eisai is dedicated to the discovery, development and production of innovative oncology therapies that can make a difference and positively impact the lives of patients and their families. This passion for people is part of Eisai's human health care (hhc) mission, which strives to better understand the needs of patients and their families to increase the benefits health care provides.
Notes to Editors
Halaven(R) (eribulin)
Eribulin is the first in the halichondrin class of microtubule dynamics inhibitors with a novel mechanism of action. Structurally eribulin is a simplified and synthetically produced version of halichondrin B, a natural product isolated from the marine sponge Halichondria okadai. Eribulin is believed to work by inhibiting the growth phase of microtubule dynamics which prevents cell division.
Eribulin is currently indicated for the treatment of women with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting, unless patients were not suitable for these treatments.[2]
Global Phase III Study 305 (EMBRACE)[3]
EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Treatment of Physician's Choice (TPC) Versus E7389) was an open-label, randomised, global, multi-centre, parallel two-arm study designed to compare overall survival in women treated with eribulin versus a TPC arm. TPC was defined as any single-agent chemotherapy, hormonal treatment or biologic therapy approved for the treatment of cancer; or palliative treatment or radiotherapy administered according to local practice. The study included 762 participants with MBC who previously had been treated with at least two and a maximum of five prior chemotherapies, including an anthracycline and a taxane. The vast majority (96%) of participants in the TPC arm received chemotherapy.
In the total Phase III EMBRACE study population, eribulin was shown to prolong median overall survival in heavily pre-treated women with MBC compared to women receiving TPC by 2.7 months (13.2 vs 10.5 HR 0.81 (95% CI 0.67, 0.96) nominal p=0.014). A pre-planned analysis of participants from Region 1 of the study (North America/Western Europe/Australia) showed a significant median overall survival benefit of eribulin over TPC of 3.0 months (nominal p=0.031).
The most commonly reported adverse reactions among people treated with eribulin in the EMBRACE study were fatigue (asthenia), a decrease in infection-fighting white blood cells (neutropenia), hair loss (alopecia), numbness and tingling in arms and legs (peripheral neuropathy), nausea and constipation. Peripheral neuropathy was the most common adverse event leading to discontinuation from eribulin, occurring in less than 5% of the women involved in the EMBRACE trial. Neutropenia only led to eribulin discontinuation for 0.6%. Death due to serious side effects, discontinuation and dose interruptions to treatment were lower in the eribulin arm of the trial compared with the TPC arm.
Global Phase III Study 301[4]
Study 301 was an open-labelled, randomised, two-parallel-arm, multicentre study of eribulin versus capecitabine in 1,102 women with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes, either in the (neo) adjuvant setting or for locally advanced or metastatic disease. Women in the study received zero to two previous chemotherapies for advanced disease.
The study opened in 2006 and the last patient was randomised in 2010. Patients were randomised to treatment with either eribulin 1.23mg/m[2] (administered intravenously over two to five minutes on days 1 and 8, every 21 days) or capecitabine 1.25 g/m2, administered orally twice daily on day 1 to 14, every 21 days.
Study 301 had a co-primary endpoint of overall survival and progression free survival. The study demonstrated a trend favouring improved overall survival with eribulin compared to capecitabine in the ITT population, although the improvement was not statistically significant. Women treated with eribulin had a median overall survival of 15.9 months (HR 0.879; 95% CI: 0.770-1.003; p=0.056) versus 14.5 months with capecitabine. The trial did not meet the pre-specified endpoint for progression-free survival, with 4.1 and 4.2 months for eribulin and capecitabine (independent review) respectively (HR 1.079; 95% CI: 0.932-1.250; p=0.305).
1--,2- and 3- year overall survival rates for eribulin versus capecitabine showed an early improvement which was maintained throughout the study (1 year, 64.4% eribulin vs 58.0% capecitabine (p=0.0351), 2 year 32.8% eribulin vs 29.8% capecitabine (p=0.324), 3 year, 17.8% eribulin vs 14.5% capecitabine (p=0.175).
(CONTINUA)
